

Curriculum Vitae

Name: Noah D. Kauff, M.D.

Office Address: Clinical Genetics Service
Memorial Sloan-Kettering Cancer Center
1275 York Avenue, Box 192
New York, NY 10021

Tel: (212) 434-5141
E-mail: kauffn@mskcc.org
Fax: (212) 434-5184

Board Certification: Year: 2000 - 2010 Name: American Board of
Obstetrics and Gynecology

Education:

May 1986 Amherst College, Amherst, MA
Bachelor of Arts, Cum Laude
Dual Majors: Chemistry and Political Science

May 1993 University of Pennsylvania School of Medicine, Philadelphia, PA
Doctor of Medicine
Honors: Obstetrics, Cardiology, Surgery, Gynecologic Oncology,
Emergency Medicine, Anesthesia, and Surgical Intensive Care

Postdoctoral Training:

July 1993 - June 1995 Intern/Resident in Obstetrics and Gynecology
Tufts University New England Medical Center, Boston, MA

July 1995 - June 1998 Resident in Obstetrics and Gynecology
Co-Executive Chief Resident
New York Medical College, New York, NY

July 2000 - July 2002 Fellow, Clinical Genetics
Memorial Sloan-Kettering Cancer Center/New York Presbyterian
Hospital.

Positions and Appointments:

July 1998 – June 2000 Attending Physician, Women's Health Care Associates, Newton, NJ
Director, Hereditary Breast and Ovarian Cancer Screening Program

July 2002 – March 2005 Clinical Assistant
Memorial Sloan-Kettering Cancer Center, New York, NY

July 2002 – March 2005 Clinical Assistant Physician
Clinical Genetics Service, Department of Medicine
Gynecology Service, Department of Surgery
Memorial Hospital for Cancer and Allied Diseases, New York, NY

April 2005 – Present Assistant Member
Memorial Sloan-Kettering Cancer Center, New York, NY

April 2005 – Present Assistant Attending Physician
Clinical Genetics Service, Department of Medicine
Gynecology Service, Department of Surgery
Memorial Hospital for Cancer and Allied Diseases, New York, NY

December 2002 – Present Instructor
Department of Medicine
Joan and Sanford I. Weill Medical College of Cornell University

Scientific and Medical Societies:

2001 - Present Fellow, American College of Obstetrics and Gynecology
1997-1998 Junior Fellow Chair, District II, Hudson Valley Section
2001 - Present American Society of Clinical Oncology
2001 - Present American Society of Human Genetics
2003 - Present American Association for Cancer Research
2005 - Present Associate Member, Society of Gynecologic Oncologists

Honors and Awards:

June 2002 Tejani Award for Research/Academic Excellence, New York Medical College
May 2002 American Society of Clinical Oncology Merit Award, Orlando, FL
May 2001 American Society of Clinical Oncology Merit Award, San Francisco, CA
March 2001 American College of Medical Genetics/March of Dimes Travel Award, Miami, FL
May 1998 New York Medical College, Resident Research Award
March 1997 Felix Rutledge Fellow in Gynecologic Oncology, MD Anderson Cancer Center
June 1997 Primary Care Update for Ob/Gyns Manuscript Competition-Honorable Mention
1989-93 John Woodruff Simpson Fellow in Medicine, Univ. of Pennsylvania School of
Medicine.

Other Activities:

New Jersey Maternal Mortality Case Review Team, March 2000 - June 2002.

Israel Cancer Research Fund – Scientific Review Panel, April 2004

Reviewer: Clinical Cancer Research, British Journal of Cancer, International Journal of
Gynecologic Cancer, Obstetrics and Gynecology, Cancer, Journal of the National
Cancer Institute, Journal of the American Medical Association.

Languages:

Spoken: English
Written: English

Active Research Support

1. DAMD17-03-1-0375 July 1, 2003-June 30, 2008
Department of Defense Breast Cancer Research Program

Physician-Scientist Training Award
Modifiers of the Efficacy of Risk-Reducing Salpingo-Oophorectomy for the Prevention of Breast and Ovarian Cancer in Carriers of *BRCA1* and *BRCA2* Mutations

Role: Principal Investigator Direct Costs: \$614,705
2. Byrne Foundation July 1, 2004-March 31, 2006
Byrne Fund Institutional Research Grant

Genetic Epidemiologic and Structural Analysis of *BRCA2* Variants of Uncertain Significance

Role: Principal Investigator Direct Costs: \$74,500

Pending Research Support

1. 1 R03 CA119265-01 Jan 1, 2006-Dec 31, 2008
Cancer Prevention Research Small Grant Program

Structural, Computational and Epidemiologic Analyses of *BRCA2* Missense Mutations

Role: Principal Investigator Direct Costs: \$100,000
2. Cooperative Group Protocol in Development

GOG 0216: Prospective Cohort Study of Gynecologic Cancer Screening and Risk-Reducing Surgery in Women with Hereditary Non-Polyposis Colon Cancer Syndrome (HNPCC)

Role: Principal Investigator

Status: Approved for further development by Protocol Committee of the GOG and the CCOP program of NCI Division of Cancer Prevention.
R01 application in response to PA-04-046 to be submitted October 1, 2005.

Completed Research Support

1. Society of Memorial Sloan-Kettering Cancer Center October 2003-September 2004
Prevention Control and Population Research Program Pilot Grant

Impact of Genetic Counseling and Testing in Non-*BRCA* Associated Hereditary Breast Cancer

Role: Principal Investigator Direct Costs: \$38,000

Publications:

1. **Kauff ND**, Chelmow D, Kawada CY. Intractable Bleeding Managed with Foley Catheter Tamponade After Dilation and Evacuation. American Journal of Obstetrics and Gynecology 1995; 173:957-8.
2. **Kauff ND**, Tejani N. Trauma in the Obstetric Patient: Evaluation and Management. Primary Care Update for Ob/Gyns 1998; 5:16-20.
3. Khalbuss WE, Rudomina D, **Kauff ND**, Chuang L, Melamed MR. Spin-Thin: A Simple, Inexpensive Technique for Preparation of Thin Layer Cervical Cytology from Liquid-Based Specimens: Data on 791 Cases. Cancer Cytopathology 2000; 90:135-42.
4. Gilbert F, **Kauff N**. Disease Genes and Chromosomes: Disease Maps of the Human Genome. Chromosome 12. Genetic Testing 2000; 4:319-33.
5. Gilbert F, **Kauff N**. Disease Genes and Chromosomes: Disease Maps of the Human Genome. Chromosome 9. Genetic Testing 2001; 5:157-74.
6. **Kauff ND**, Scheuer L, Robson ME, Glogowski E, Kelly B, Barakat R, Heerdt A, Borgen PI, Davis JG, Offit K. Insurance Reimbursement for Risk-Reducing Mastectomy and Oophorectomy in Women with *BRCA1* or *BRCA2* Mutations. Genetics in Medicine 2001; 6:422-5.
7. Scheuer L, **Kauff N**, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in *BRCA* Mutation Carriers. Journal of Clinical Oncology 2002; 20:1260-8.
8. **Kauff ND**, Satagopan JM, Scheuer L, Robson ME, Castiel M, Nafa K, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Offit K. Risk-Reducing Salpingo-Oophorectomy in Women with *BRCA1* and *BRCA2* Mutations. New England Journal of Medicine 2002; 346:1609-15.
9. **Kauff ND**, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Rapaport B, Frank TS, Nafa K, Parmigiani G, Offit K. Incidence of Non-Founder *BRCA1* and *BRCA2* Mutations in High-Risk Ashkenazi Breast and Ovarian Cancer Families. Journal of Medical Genetics 2002; 39:611-614.
10. Offit K, Gilad S, Paglin S, Kolachana P, Roisman LC, Nafa K, Yeugelewitz V, Gonzales M, Robson M, McDermott D, Hanson Pierce H, **Kauff N**, Einat P, Jhanwar S, Satagopan J, Oddoux C, Ellis N, Skaliter R, Yahalom J. Rare Variants of *ATM* and Risk for Hodgkin's Disease and Radiation-Associated Breast Cancers. Clinical Cancer Research 2002; 8:3813-9.
11. Satagopan JM, Boyd J, **Kauff N**, Robson M, Scheuer L, Narod S, Offit K. Ovarian Cancer Risk in Ashkenazi Jewish Carriers of *BRCA1* and *BRCA2* Mutations. Clinical Cancer Research 2002; 8:3776-81.
12. **Kauff ND***, Brogi E*, Scheuer L, Pathak DR, Borgen PI, Hudis CA, Offit K, Robson ME. Epithelial Lesions in Prophylactic Mastectomy Specimens from Women with *BRCA* Mutations. Cancer 2003; 97:1601-8. (*contributed equally to this work)
13. Hensley ML, Robson ME, **Kauff ND**, Korytowsky B, Castiel M, Ostroff J, Hurley K, Hann LE, Colon J, Spriggs D. Pre- and Post-Menopausal High-Risk Women Undergoing Screening for Ovarian Cancer: Anxiety, Risk Perceptions, and Quality of Life. Gynecologic Oncology 2003;

89:440-6.

14. Robson ME, Brogi E, **Kauff ND**. Proliferative Epithelial Lesions in Women at Hereditary Risk for Breast Cancer. American Journal of Oncology Review 2003; 2:540-4.
15. Kirchoff T, Satagopan JM, **Kauff ND**, Huang H, Kolachana P, Palmer C, Rapaport H, Nafa K, Ellis NA, Offit K. Frequency of *BRCA1* and *BRCA2* Mutations in Unselected Ashkenazi Jewish Patients with Colorectal Cancer. Journal of the National Cancer Institute 2004;96:68-70.
16. **Kauff ND**, Goldfrank D, Barakat RR. Preventing *BRCA*-Related Cancers: The Case for Oophorectomy. OBG Management 2004; 16:56-67.
17. **Kauff ND**, Barakat RR. Surgical Risk-Reduction in Carriers of *BRCA* Mutations: Where Do We Go from Here? Gynecologic Oncology 2004; 93:277-9.
18. Kirchoff T*, **Kauff ND***, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K. *BRCA* Mutations and Risk of Prostate Cancer in Ashkenazi Jews. Clinical Cancer Research 2004; 10: 2918-21. (*contributed equally to this work)
19. Amsterdam A, **Kauff N**, Castiel M. Managing Menopause in the Cancer Patient. Female Patient 2004; 29(supp):46-51.
20. Amsterdam A, Jakubowski A, Castro-Malaspina H, Baxi E, **Kauff N**, Krychman M, Stier E, Castiel M. Treatment of menorrhagia in women undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34:363-6.
21. Dupont J, Tanwar MK, Thaler HT, Fleisher M, **Kauff N**, Hensley ML, Sabbatini P, Anderson S, Aghajanian C, Holland EC, Spriggs DR. Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40. Journal of Clinical Oncology 2004; 22:3330-9.
22. Robles-Díaz L, Goldfrank DJ, **Kauff ND**, Robson M, Offit K. Hereditary Ovarian Cancer in Ashkenazi Jews. Familial Cancer 2004; 3:259-64.
23. Siddiqui R, Onel K, Facio F, Nafa K, Diaz LR, **Kauff N**, Huang H, Robson M, Ellis N, Offit K. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Familial Cancer 2005; 4:177-81.
24. **Kauff ND**, Hurley KE, Hensley ML, Robson ME, Lev G, Goldfrank D, Castiel M, Brown CL, Ostroff JS, Hann LE, Offit K, Barakat RR. Ovarian Cancer Screening in Women at Intermediate Risk - Impact on Quality of Life and Need for Invasive Follow-up. Cancer 2005; 104: 314-20.
25. Society of Gynecologic Oncologists: Clinical Practice Committee. Statement on Prophylactic Salpingo-oophorectomy. Gynecologic Oncology. 2005; 98:179-181.(**Kauff ND** - Principal Author).
26. **Kauff ND**, Mitra M, Robson ME, Hurley KE, Chuai S, Goldfrank D, Wadsworth E, Lee J, Cigler T, Borgen PI, Norton L, Barakat RR, Offit K. Risk of Ovarian Cancer in *BRCA1* and *BRCA2* Mutation Negative Hereditary Breast Cancer Families. Journal of the National Cancer Institute. 2005; 97:1382-4.

Book Chapters:

1. **Kauff ND**, Barakat RR, Offit K. Risk-Reducing Salpingo-Oophorectomy in Patients with *BRCA1*

and *BRCA2* Mutations. In: Devita VT Jr., Hellman S, Rosenberg SA, eds. Progress in Oncology 2003. Sudbury: Jones and Bartlett; 2003.

Selected Abstracts:

1. **Kauff N**, Scheuer L, Robson M, Barakat R, Borgen P, Heerdt A, Hudis C, Norton L, Davis J, Offit K. Insurance Reimbursement for Risk-Reducing Surgeries in *BRCA1* and *BRCA2* Heterozygotes. Presented at the 2001 Annual Meeting of American College of Medical Genetics, Miami, FL, March 2001.
2. Scheuer LM, Brogi E, **Kauff N**, Kelly B, Baum R, Glowgowski E, Hull J, Pierce H, Borgen P, Heerdt A, Hudis C, Norton L, Offit K, Robson M. Pathologic Findings at Risk-Reducing Mastectomy in *BRCA1* and *BRCA2* Heterozygotes. Presented at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 2001.
3. **Kauff ND**, Scheuer LM, Kelly B, Finch A, Baum RC, Glogowski E, Greene J, Hull J, Pierce H, Borgen P, Heerdt A, Hudis C, Norton L, Robson ME, Offit K. Differences in Breast Cancer Presentation in Women with and without *BRCA1* and *BRCA2* Mutations. Presented at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 2001.
4. **Kauff ND**, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Frank TS, Nafa K, Parmigiani G, Offit K. Incidence of Non-Founder *BRCA1* and *BRCA2* Mutations in High-Risk Ashkenazi Breast and Ovarian Cancer Families. Presented at the 2002 Annual Meeting of the American College of Medical Genetics, New Orleans, LA, March 2002.
5. Offit K, **Kauff N**, Satagopan J, Scheuer L, Robson M, Baum R, Facio F, Glogowski E, Hull J, Pierce H, Siegel B, Finch A, Huang H, Castiel M, Hensley M, Hudis C, Borgen P, Norton N, Barakat R. Risk-Reducing Salpingo-Oophorectomy in Women with *BRCA1* and *BRCA2* Mutations. Plenary Presentation at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2002.
6. Satagopan J, Boyd J, **Kauff N**, Robson M, Scheuer L, Narod S, Offit K. Ovarian Cancer Risk in Ashkenazi Jewish Carriers of *BRCA1* and *BRCA2* Mutations. Presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2002.
7. **Kauff N**, Offit K, Gilad S, Paglin S, Kolachana P, Roisman L, Nafa K, Yeugelewitz V, Gonzales M, Robson M, McDermott D, Hanson Pierce H, Rapaport B, Einat P, Jhanwar S, Satagopan J, Oddoux C, Ellis N, Skaliter R, Yahalom J. Mutations of ATM and Risk for Hodgkin's Disease and Radiation-Associated Breast Cancers. Presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2002.
8. Offit K, **Kauff N**, Scheuer L, Huang H, Rapaport B, Finch A, Baum R, Castiel M, Robson M, Hudis C, Borgen P, Barakat R, Norton L. Risk-Reducing Salpingo-Oophorectomy in Women with *BRCA1* and *BRCA2* Mutations. Presented in Oncology Highlights 2002 at the 27th Annual Congress of the European Society of Medical Oncology, Nice, France, October 2002.
9. Huang H, Scheuer LM, **Kauff N**, Robson M, Baum R, Borgen PI, Hudis C, Norton L, Offit K. Breast cancer screening compliance in *BRCA1* and *BRCA2* heterozygotes. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 2003.
10. Robson ME, Morris E, **Kauff N**, Scheuer L, Borgen PI, Hudis C, Norton L, Offit K. Breast Cancer screening utilizing magnetic resonance imaging (MRI) in carriers of *BRCA* mutations. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago,

IL, June 2003.

11. Kirchoff T, **Kauff N**, Kolachana P, Mitra N, Satagopan J, Huang H, Shia J, Palmer C, Nafa K, Ellis N, Offit K. *BRCA* mutations and the risk of prostate and colorectal cancer in Ashkenazi Jews. Presented at the 53th Annual Meeting of the American Society of Human Genetics, Los Angeles, CA, November 2003.
12. **Kauff ND**, Hurley KE, Hensley ML, Robson ME, Lev G, Castiel ML, Brown CL, Ostroff JS, Hann LE, Offit K, Barakat RR. Ovarian Cancer Screening in Women at Increased Risk – Impact on Quality of Life and Utilization of Medical Resources: Results of an Interim Analysis. Plenary Presentation at the 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, February 2004.
13. Stier EA, Wang M, Chuai S, Hirsch-Bloch L, **Kauff N**, Castiel M. Incidence of and risk factors for clinically significant pathology in endometrial polyps from patients on tamoxifen. Presented at the 52nd Annual Meeting of the American College of Obstetricians and Gynecologists, Philadelphia, PA, May 2004.
14. **Kauff N**, Cigler T, Hurley K, Huang H, Rapaport H, Wadsworth E, Robson M, Norton L, Barakat R, Offit K. Incidence of ovarian cancer in *BRCA*-negative hereditary breast cancer families. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 2004.
15. Kemel Y, **Kauff ND**, Robson ME, Goldfrank DJ, Wadsworth E, Diiorio T, Boyd J, Hudis CA, Barakat RR, Offit K. Four Year Follow-up of Outcomes Following Risk-Reducing Salpingo-Oophorectomy in *BRCA* Mutation Carriers. Presented at the 41th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2005.
16. **Kauff ND**, Wadsworth E, Goldfrank DJ, Robson ME, Lee J, Lafaro K, Aaron S, Norton L, Barakat RR, Offit K. Association of Personal and Family History with Decision to Undergo Risk-Reducing Salpingo-Oophorectomy in *BRCA* Mutation Carriers. Presented at the 41th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2005.
17. Goldfrank DJ, Lee J, **Kauff ND**, Hurley KE, Balistreri L, Hellowell J, Borgen PI, Hudis CA, Offit K, Robson ME. Adherence to mammogram (MMG) screening guidelines in *BRCA*1/2 mutation carriers. Presented at the 41th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2005.